Cover Image
Market Research Report

Stroke prevention in Atrial Fibrillation Market and Forecast Analysis to 2024

Published by Datamonitor Healthcare Product code 365168
Published Content info 369 Pages
Delivery time: 1-2 business days
Price
Back to Top
Stroke prevention in Atrial Fibrillation Market and Forecast Analysis to 2024
Published: March 15, 2018 Content info: 369 Pages
Description

Overview

Atrial fibrillation is the most common chronic cardiac arrhythmia, and is usually associated with other cardiovascular diseases. Atrial fibrillation is characterized by an irregular heartbeat, where the atria may not contract properly. While the disease is not considered life-threatening in itself, atrial fibrillation is one of the leading causes of stroke, with the disease conferring a fivefold increased risk.

Market Snapshot

  • Strong efficacy and safety data are expected to drive NOACs at the expense of warfarin over the forecast period.
  • Survey of 213 cardiologists in the US, Japan, and five major EU markets sheds light on prescribing trends in SPAF.
  • Diagnosed prevalent cases of atrial fibrillation are estimated to increase by more than 40% during the forecast period.
  • The development of antidotes for the NOAC drug class is likely to substantially increase their uptake.
  • Drug developers will need to identify reversal agents in order for pipeline medications to be able to compete with marketed drugs.
  • EU payers limit use due to high cost, while US payers support uptake.
Table of Contents
Product Code: DMKC12571

TABLE OF CONTENTS

FORECAST: STROKE PREVENTION IN ATRIAL FIBRILLATION (SPAF) (Published on 15 March 2018)

  • OVERVIEW
  • RECENT FORECAST UPDATES
  • MARKET DYNAMICS
  • FORECAST AND FUTURE TRENDS
  • MARKET DEFINITION AND METHODOLOGY
  • PRIMARY RESEARCH METHODOLOGY
  • BIBLIOGRAPHY
  • PRODUCT PROFILE: ELIQUIS
  • PRODUCT PROFILE: PRADAXA
  • PRODUCT PROFILE: SAVAYSA
  • PRODUCT PROFILE: XARELTO

TREATMENT: STROKE PREVENTION IN ATRIAL FIBRILLATION (Published on 11 December 2017)

  • OVERVIEW
  • EXECUTIVE SUMMARY
  • PRIMARY RESEARCH METHODOLOGY
  • DISEASE DEFINITION AND DIAGNOSIS
  • CURRENT TREATMENT OPTIONS
  • PRESCRIBING TRENDS

EPIDEMIOLOGY: ATRIAL FIBRILLATION (Published on 08 December 2017)

  • OVERVIEW
  • EXECUTIVE SUMMARY
  • DISEASE BACKGROUND
  • METHODOLOGY
  • FORECAST
  • EPIDEMIOLOGIST INSIGHT
  • STRENGTHS AND LIMITATIONS
  • BIBLIOGRAPHY
  • APPENDIX: ADDITIONAL SOURCES

MARKETED DRUGS: STROKE PREVENTION IN ATRIAL FIBRILLATION (SPAF) (Published on 15 March 2018)

  • OVERVIEW
  • PRODUCT OVERVIEW
  • PRODUCT PROFILE: ELIQUIS
  • PRODUCT PROFILE: PRADAXA
  • PRODUCT PROFILE: SAVAYSA
  • PRODUCT PROFILE: XARELTO

NOACS PRICING, REIMBURSEMENT, AND ACCESS (Published on 10 May 2017)

  • OVERVIEW
  • EXECUTIVE SUMMARY
  • REGULATORY LABELS
  • GLOBAL PAYER AND KEY OPINION LEADER INSIGHTS
  • US PRICING
  • US REIMBURSEMENT
  • JAPAN
  • PRICING IN THE FIVE MAJOR EU MARKETS
  • FRANCE
  • GERMANY
  • ITALY
  • SPAIN
  • UK
  • METHODOLOGY

PIPELINE: STROKE PREVENTION IN ATRIAL FIBRILLATION (SPAF) (Published on 15 March 2018)

  • OVERVIEW
  • PIPELINE TRENDS

LIST OF FIGURES

  • Figure 1: SPAF - Current and future market dynamics analysis
  • Figure 2: Datamonitor Healthcare's assessment summary of key marketed drugs for SPAF
  • Figure 3: SPAF drug sales across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 4: Trajectories of Xarelto, Eliquis, and Pradaxa sales for SPAF across the US, Japan, and five major EU markets, 2017-26
  • Figure 5: Savaysa sales for SPAF across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 6: Trajectories of Xarelto and Eliquis sales for SPAF across the US, Japan, and five major EU markets, 2017-26
  • Figure 7: Patient-based forecast methodology for SPAF
  • Figure 8: Price sources and calculations, by country
  • Figure 9: Eliquis for SPAF - SWOT analysis
  • Figure 10: Datamonitor Healthcare's drug assessment summary of Eliquis for SPAF
  • Figure 11: Datamonitor Healthcare's drug assessment summary of Eliquis for SPAF
  • Figure 12: Eliquis sales for SPAF across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 13: Pradaxa for SPAF - SWOT analysis
  • Figure 14: Datamonitor Healthcare's drug assessment summary of Pradaxa for SPAF
  • Figure 15: Datamonitor Healthcare's drug assessment summary of Pradaxa for SPAF
  • Figure 16: Pradaxa sales for SPAF across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 17: Savaysa for SPAF - SWOT analysis
  • Figure 18: Datamonitor Healthcare's drug assessment summary of Savaysa for SPAF
  • Figure 19: Datamonitor Healthcare's drug assessment summary of Savaysa for SPAF
  • Figure 20: Savaysa sales for SPAF across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 21: Xarelto for SPAF - SWOT analysis
  • Figure 22: Datamonitor Healthcare's drug assessment summary of Xarelto for SPAF
  • Figure 23: Datamonitor Healthcare's drug assessment summary of Xarelto for SPAF
  • Figure 24: Xarelto sales for SPAF across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 25: Mean percentage of atrial fibrillation patients diagnosed with each type of atrial fibrillation in the US, Japan, and five major EU markets, by country
  • Figure 26: Mean percentage of atrial fibrillation patients in each category of atrial fibrillation in the US, Japan, and five major EU markets, by country
  • Figure 27: Mean percentage of valvular atrial fibrillation patients receiving long-term stroke prevention treatment, by country
  • Figure 28: Mean percentage of valvular atrial fibrillation patients receiving each of the top five antiplatelet/anticoagulation therapies at first line, by country
  • Figure 29: Mean percentage of valvular atrial fibrillation patients receiving each of the top five antiplatelet/anticoagulation therapies at second line, by country
  • Figure 30: Mean percentage of non-valvular atrial fibrillation patients with CHADS-VASc scores of 0 receiving long-term stroke prevention treatment, by country
  • Figure 31: Mean percentage of non-valvular atrial fibrillation patients with CHADS-VASc scores of 0 receiving each of the top five therapies at first line, by country
  • Figure 32: Mean percentage of non-valvular atrial fibrillation patients with CHADS-VASc scores of 0 receiving each of the top five therapies at second line, by country
  • Figure 33: Mean percentage of non-valvular atrial fibrillation patients with CHADS-VASc scores of 1 receiving long-term stroke prevention treatment, by country
  • Figure 34: Mean percentage of non-valvular atrial fibrillation patients with CHADS-VASc scores of 1 receiving each of the top five therapies at first line, by country
  • Figure 35: Mean percentage of non-valvular atrial fibrillation patients with CHADS-VASc scores of 1 receiving each of the top five therapies at second line, by country
  • Figure 36: Mean percentage of non-valvular atrial fibrillation patients with CHADS-VASc scores ≥2 receiving long-term stroke prevention treatment, by country
  • Figure 37: Risk of adverse events in patients with various CHADS-VASc scores, Swedish Atrial Fibrillation cohort study, 2005
  • Figure 38: Mean percentage of non-valvular atrial fibrillation patients with CHADS-VASc scores ≥2 receiving each of the top five therapies at first line, by country
  • Figure 39: Mean percentage of non-valvular atrial fibrillation patients with CHADS-VASc scores ≥2 receiving each of the top five therapies at second line, by country
  • Figure 40: Clinical implications of AF
  • Figure 41: Prevalence of co-morbidities in patients with AF, by organ system
  • Figure 42: Trend in diagnosed prevalent cases of AF in the US, Japan, and five major EU markets, by country, 2016-36
  • Figure 43: Absolute change in diagnosed prevalent cases of AF in the US, Japan, and five major EU markets, by country, 2016-36
  • Figure 44: Trend in age-specific diagnosed prevalent cases of AF in the US, Japan, and five major EU markets, by country, 2016-36
  • Figure 45: Eliquis for SPAF - SWOT analysis
  • Figure 46: Datamonitor Healthcare's drug assessment summary of Eliquis for SPAF
  • Figure 47: Datamonitor Healthcare's drug assessment summary of Eliquis for SPAF
  • Figure 48: Eliquis sales for SPAF across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 49: Pradaxa for SPAF - SWOT analysis
  • Figure 50: Datamonitor Healthcare's drug assessment summary of Pradaxa for SPAF
  • Figure 51: Datamonitor Healthcare's drug assessment summary of Pradaxa for SPAF
  • Figure 52: Pradaxa sales for SPAF across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 53: Savaysa for SPAF - SWOT analysis
  • Figure 54: Datamonitor Healthcare's drug assessment summary of Savaysa for SPAF
  • Figure 55: Datamonitor Healthcare's drug assessment summary of Savaysa for SPAF
  • Figure 56: Savaysa sales for SPAF across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 57: Xarelto for SPAF - SWOT analysis215 Figure 58: Datamonitor Healthcare's drug assessment summary of Xarelto for SPAF
  • Figure 59: Datamonitor Healthcare's drug assessment summary of Xarelto for SPAF
  • Figure 60: Xarelto sales for SPAF across the US, Japan, and five major EU markets, by country, 2017-26

LIST OF TABLES

  • Table 1: SPAF drug sales across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 2: Proportion of SPAF total market sales according to patient subgroup (%), 2017-26
  • Table 3: SPAF total market sales according to patient subgroup ($m), 2017-26
  • Table 4: Average cost of treatment, CAGRs, and proportions of sales and patients across the US, Japan, and five major EU markets, by country, 2017-26
  • Table 5: Exchange rates used for calculating prices
  • Table 6: Cardiologists surveyed for the SPAF primary research study, 2017
  • Table 7: Eliquis drug profile
  • Table 8: Eliquis pivotal trial data in SPAF
  • Table 9: Eliquis late-phase trial data in SPAF
  • Table 10: Eliquis ongoing late-phase clinical trial in SPAF
  • Table 11: Eliquis sales for SPAF across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 12: Pradaxa drug profile
  • Table 13: Pradaxa pivotal trial data in SPAF
  • Table 14: Pradaxa late-phase trial data in SPAF
  • Table 15: Pradaxa ongoing late-phase clinical trials in SPAF
  • Table 16: Pradaxa sales for SPAF across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 17: Savaysa drug profile
  • Table 18: Savaysa pivotal trial data in SPAF
  • Table 19: Savaysa late-phase trial data in SPAF
  • Table 20: Savaysa ongoing late-phase clinical trials in SPAF
  • Table 21: Savaysa sales for SPAF across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 22: Xarelto drug profile
  • Table 23: Xarelto pivotal trial data in SPAF
  • Table 24: Xarelto late-phase trial data in SPAF
  • Table 25: Xarelto ongoing late-phase clinical trial in SPAF
  • Table 26: Xarelto sales for SPAF across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 27: Cardiologists surveyed for the stroke prevention in atrial fibrillation primary research study, 2017
  • Table 28: Overview of different atrial fibrillation classifications
  • Table 29: Overview of risk factors for atrial fibrillation
  • Table 30: Mean percentage of valvular atrial fibrillation patients who have co-morbidities in the US, Japan, and five major EU markets, by co-morbidity and country (%)
  • Table 31: Mean percentage of non-valvular atrial fibrillation patients who have co-morbidities in the US, Japan, and five major EU markets, by co-morbidity and country (%)
  • Table 32: Atrial fibrillation symptoms
  • Table 33: Overview of the CHA2DS2-VASc scoring system
  • Table 34: Treatments available for stroke prevention in atrial fibrillation across the US, Japan, and five major EU markets
  • Table 35: Sources used for the epidemiological analysis of diagnosed prevalence of AF in the US, Japan, and five major EU markets, by country
  • Table 36: Sources used for the epidemiological analysis of diagnosed incidence of AF in the US, Japan, and five major EU markets, by country
  • Table 37: Diagnosed prevalent cases of AF in the US, Japan, and five major EU markets, by country, 2016-36
  • Table 38: Age-specific diagnosed prevalent cases of AF in the US, Japan, and five major EU markets, by country, 2016
  • Table 39: Gender-specific diagnosed prevalent cases of AF in the US, Japan, and five major EU markets, by country, 2016
  • Table 40: Diagnosed incident cases of AF in the US, Japan, and five major EU markets, by country, 2016-36
  • Table 41: Key marketed drugs for SPAF
  • Table 42: Eliquis drug profile
  • Table 43: Eliquis pivotal trial data in SPAF
  • Table 44: Eliquis late-phase trial data in SPAF
  • Table 45: Eliquis ongoing late-phase clinical trial in SPAF
  • Table 46: Eliquis sales for SPAF across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 47: Pradaxa drug profile
  • Table 48: Pradaxa pivotal trial data in SPAF
  • Table 49: Pradaxa late-phase trial data in SPAF
  • Table 50: Pradaxa ongoing late-phase clinical trials in SPAF
  • Table 51: Pradaxa sales for SPAF across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 52: Savaysa drug profile
  • Table 53: Savaysa pivotal trial data in SPAF
  • Table 54: Savaysa late-phase trial data in SPAF
  • Table 55: Savaysa ongoing late-phase clinical trials in SPAF
  • Table 56: Savaysa sales for SPAF across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 57: Xarelto drug profile
  • Table 58: Xarelto pivotal trial data in SPAF
  • Table 59: Xarelto late-phase trial data in SPAF
  • Table 60: Xarelto ongoing late-phase clinical trial in SPAF
  • Table 61: Xarelto sales for SPAF across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 62: Marketed NOAC products and approved indications in the US, Japan, and five major EU markets
  • Table 63: Levers impacting access to anticoagulants in the five major EU markets
  • Table 64: Levers impacting access to NOACs in the US and five major EU markets
  • Table 65: French and German HTA decisions
  • Table 66: US pricing of key marketed drugs
  • Table 67: Prior authorization criteria for NOACs in six major health plans
  • Table 68: Formulary placement of NOACs in selected 2016 commercial formularies
  • Table 69: Formulary placement of NOACs in top 10 2016 Medicare Part D formularies
  • Table 70: Formulary placement of NOACs in selected large Medicaid states' preferred drug lists
  • Table 71: Pricing premiums given to medicines that can demonstrate benefit over comparators in Japan
  • Table 72: Pricing of NOACs in Japan
  • Table 73: Price calculation methodologies for NOACs in Japan
  • Table 74: Pricing of key NOACs in the five major EU markets
  • Table 75: Transparency Commission's ASMR ratings and pricing implications
  • Table 76: Transparency Committee's SMR ratings and pricing implications
  • Table 77: Transparency Commission's assessment of SPAF treatments in France
  • Table 78: Transparency Commission's assessment of VTE treatments in France
  • Table 79: Transparency Commission's assessment of Praxbind (reversal agent for Pradaxa) in France
  • Table 80: G-BA assessment of key SPAF therapies in Germany
  • Table 81: G-BA assessment of key VTE therapies in Germany
  • Table 82: AIFA's reimbursement decisions for NOACs in Italy
  • Table 83: Reimbursement conditions for antidotes in Italy
  • Table 84: Local formulary decisions for NOACs in Italy
  • Table 85: Spain regional assessments of anticoagulants
  • Table 86: NICE assessments of key SPAF therapies in the UK
  • Table 87: NICE assessments of key VTE therapies in the UK
  • Table 88: Regional formulary decisions for SPAF therapies in the UK
  • Table 89: Regional formulary decisions for VTE therapies in the UK
  • Table 90: SMC decisions on key SPAF therapies
  • Table 91: SMC decisions on key VTE therapies
  • Table 92: SMC decisions on key antidotes
  • Table 93: Price sources and calculations, by country
  • Table 94: Exchange rates used for calculating prices
Back to Top